Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–60 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Drug Use Clear all
Completed No phase listed Observational

Ragweed Observational Study

NCT01398137
View directory record Official record
Conditions
Ragweed Allergy
Interventions
Not listed
Lead sponsor
Circassia Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Owensboro, Kentucky • Minneapolis, Minnesota • Plymouth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 19, 2026, 3:29 AM EDT
Active, not recruiting Not applicable Interventional

Supporting Treatment Access and Recovery Through Linkage and Support

NCT05713695
View directory record Official record
Conditions
Mental Health Disorders, Substance Use Disorders
Interventions
Full MISSION, Linkage Only Delivered by a Peer Specialist
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

NCT07225738
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Non-Interventional Study
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
11
States / cities
Goodyear, Arizona • Duarte, California • Huntington Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Not listed Phase 2 Interventional

Improving Hand Use in Multiple Sclerosis

NCT01081275
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
CI Therapy, CAM treatments
Behavioral
Lead sponsor
National Multiple Sclerosis Society
Other
Eligibility
21 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 19, 2026, 3:29 AM EDT
Completed No phase listed Observational

Delphinus SoftVue Prospective Case Collection - ARM 2

NCT02977247
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Non-Interventional, Automated Whole Breast Ultrasound
Other · Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Los Angeles, California • Miami Beach, Florida • Savannah, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 19, 2026, 3:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Characterization of Product Use in Smokers Switching From Cigarettes to a RELX Electronic Nicotine Delivery System

NCT04708106
View directory record Official record
Conditions
Electronic Cigarette Use
Interventions
RELX ENDS Tobacco Flavor, RELX ENDS Menthol Flavor, RELX ENDS Tobacco and Menthol Flavors
Other
Lead sponsor
Cheerain HK Limited
Industry
Eligibility
22 Years to 65 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
Bentonville, Arkansas • Lexington, Kentucky • Springfield, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 19, 2026, 3:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

NCT02696291
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 19, 2026, 3:29 AM EDT
Recruiting Phase 2 Interventional

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions
Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
12 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
174
States / cities
Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders

NCT02450240
View directory record Official record
Conditions
Depression, Anxiety, Eating Disorders, Drug Use Disorders
Interventions
standardized diagnostic assessment, self-report questionnaires, behavioral tasks, physiological measurements, structural and functional magnetic resonance imaging and EEG, biomarker and microbiome assessments, blood to derive induced pluripotent stem cells, genetic and epigenetic assessments
Behavioral · Other
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
1,271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 19, 2026, 3:29 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Multi-System Analysis of Opioid Receptor Binding

NCT05528848
View directory record Official record
Conditions
Healthy, Opioid Use Disorder
Interventions
Carfentanil, C-11, Naloxone, Loperamide Hydrochloride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 19, 2026, 3:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Avonex 15 Year Long Term Follow-up Study

NCT00525343
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Buffalo, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 19, 2026, 3:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 3:29 AM EDT